Inhibikase Therapeutics, Inc. (IKT) ownership: Top institutional holder: Sands Capital Alternatives, LLC ($21.87M). Insider activity: Net Seller (0 buys, 3 sells). SEC EDGAR first-party data.
| Holder | Shares | Market Value | Reported |
|---|---|---|---|
| Sands Capital Alternatives, LLC | 13018965.00 | $21.87M | 2026-03-31 |
| Soleus Capital Management, L.P. | 10875000.00 | $18.27M | 2026-03-31 |
| Fairmount Funds Management LLC | 8625000.00 | $14.49M | 2026-03-31 |
| Trails Edge Capital Partners, LP | 8057345.00 | $13.54M | 2026-03-31 |
| ADAR1 Capital Management, LLC | 6606572.00 | $11.10M | 2026-03-31 |
| BlackRock, Inc. | 6303433.00 | $10.59M | 2026-03-31 |
| Blackstone Inc. | 5938276.00 | $9.98M | 2026-03-31 |
| Siren, L.L.C. | 5850000.00 | $9.83M | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-02-21 | |
| Sell | null | 2026-02-21 | |
| Sell | null | 2026-02-21 |
Back to IKT overview · IKT earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.